6 results about "Median lethal dose" patented technology

The invention relates to the technical field of drug side reaction risk prediction, in particular to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises a data acquisition module used for integrating multi-source time series data, including medication dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; the cumulative effect analysis module is used for calculating a drug attenuation factor, a binding dose and median lethal dose quantitative cumulative effect intensity based on first-order elimination kinetics, and capturing drug metabolic dynamics; due to the fact that the interaction influence effect possibly exists between the drugs, the influence coefficient analysis module is used for adopting elastic network regression and analyzing the drug main effect and the drug combination interaction effect, and determining the main influence coefficient and the interaction influence coefficient of the drugs on each clinical index; and the risk prediction module is used for weighting and optimizing decision tree sorting through the abnormal contribution degree, and outputting the risk probability of each side reaction in combination with a random forest algorithm.

A neutralizing antibody capable of potent neutralization of SFTSVs and the use thereof. The neutralizing antibody specifically recognizes amino acids at 26th, 39th, 42nd, 46th, 50th and 53rd sites of the sub-domain I and amino acids at 260th, 263rd, 268th, 271st and 301st sites of the sub-domain III of the extracellular domain of SFTSVGn. The neutralization activity of the neutralizing antibody ZS004-1C5 in inhibiting SFTSV(DBV) infection of half of cells is 67 thousands times that of MAb4-5 which is the only one fully-humanized neutralizing antibody known so far. Simply by means of one inoculation, the neutralizing antibody ZS004-1C5 can prevent STAT1- / - immunodeficient mice from a lethal attack caused by viruses with a 10-fold median lethal dose (LD50), and therefore has the potential to be put into clinical treatment, and may improve the survival rate for patients with a severe fever with thrombocytopenia syndrome (SFTS) and reduce the risk for intensive care.

This invention discloses a method and its application for creating stress-resistant mutants of common bean using chemical mutagenesis. The main steps include: determining the screening concentration of hydroxyproline (Hyp), determining the median lethal dose of ethyl methanesulfonate (EMS), and subculturing the stress-resistant mutants. After 3-5 subcultures, the stress-resistant mutants screened by this invention ultimately yielded 31 cotyledonary nodes of common bean resistant to hydroxyproline (Hyp), with a mutation rate of 8.16%. This invention can induce mutagenesis and directionally screen for stress-resistant common bean mutants, providing material support for stress-resistant breeding of common bean.

The present application relates to the technical field of drug side reaction risk prediction, and particularly relates to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises: a data acquisition module for integrating multi-source time series data, including drug dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; a cumulative effect analysis module for calculating a drug attenuation factor based on first-order elimination kinetics, quantifying the cumulative effect intensity in combination with the dosage and median lethal dose, and capturing the drug metabolism dynamics; since there may be interactive effects between drugs, an influence coefficient analysis module is used to analyze the drug main effect and the joint drug interaction effect by using elastic network regression, and to determine the main influence coefficient and the interaction influence coefficient of the drug on each clinical index; a risk prediction module for optimizing the decision tree sorting by the abnormal contribution degree weighting, and outputting the risk probability of each side reaction in combination with the random forest algorithm.

The application discloses a nanobody B12 and related biomaterials and applications thereof, and belongs to the field of immunotherapy biotechnology and pharmaceuticals, and particularly relates to the nanobody B12 and related biomaterials and applications thereof. The nanobody or antigen-binding fragment containing the nanobody targeting botulinum toxin type B has three complementarity determining regions CDR1, CDR2 and CDR3; the amino acid sequence of CDR1 is SEQ ID No. 1, the amino acid sequence of CDR2 is SEQ ID No. 2, and the amino acid sequence of CDR3 is SEQ ID No. 3. The nanobody B12 is fused with the Fc segment (hFc) of human immunoglobulin to obtain a fusion protein, and the obtained B12-hFc can effectively block the infection of botulinum toxin type B, and can resist 20LD 50 The half lethal dose ED of botulinum toxin is 0.28 μg. 50 ​

The invention discloses a broad-spectrum Chinese herbal medicine compound for resisting main pathogenic bacteria of prawns as well as a preparation method and application of the broad-spectrum Chinese herbal medicine compound, and belongs to the technical field of aquaculture disease control. The compound consists of sanguisorba officinalis, myrobalan, coptis chinensis and smoked plum in a mass ratio of 1: 4: 4, and is prepared by the steps of crushing and sieving the raw materials, mixing in proportion, decocting in water, concentrating and sterilizing. The compound has a remarkable broad-spectrum antibacterial effect on six main pathogenic bacteria causing common diseases such as penaeus vannamei royal death disease, red-leg disease, luminescence disease and enteritis disease, the average inhibition zone reaches 22.08 mm, the minimum inhibitory concentration is as low as 2.67 mg / mL, the safety is high, the median lethal dose is larger than 10000 mg / kg, and the actual dosage is far lower than a toxicity threshold value. Meanwhile, the compound also can obviously improve the activity of acid phosphatase and alkaline phosphatase of the prawns to two times that of a control group, and the immune protection rate reaches 46.67%. When the feed additive is added into a prawn feed according to the addition amount of 1300-1500mg / kg, common bacterial diseases of prawns can be effectively prevented and treated, and hepatopancreas and midgut tissues of the prawns are not damaged.